Specialty tier coinsurance is the cost-sharing structure that Medicare Part D and most commercial formularies apply to their highest tier, usually Tier 4 or Tier 5, reserved for biologics, oncology drugs, and other complex therapies that CMS classifies as specialty in 2026. Unlike a flat copay ($10 or $47 per fill), specialty tier cost-sharing is coinsurance, a percentage of the drug's negotiated price. CMS sets the specialty tier threshold at $950 per month for 2026: any Part D drug priced above that line can be placed on the specialty tier, and formulary rules require every Part D plan to charge coinsurance rather than a flat copay for those drugs. That single design choice is why a $7,000-per-month drug like Humira or Stelara can generate a $1,750 to $2,300 bill in a single fill at a 25% to 33% coinsurance rate, far more than the $47 a Tier 3 brand drug typically costs.
KFF's 2026 Medicare Part D cost-sharing analysis found that the median specialty tier coinsurance is 25% among standalone prescription drug plans (PDPs) and 28% among Medicare Advantage prescription drug plans (MA-PDs), with the range across all national and near-national plans running 25% to 33%. Commercial (employer or marketplace) plans often mirror this structure, though some cap specialty tier cost-sharing at a fixed dollar amount per fill (commonly $100 to $250) rather than leaving it as an open percentage. The 2026 Part D standard deductible is $615, meaning a beneficiary typically pays the full negotiated price for their specialty drug until the deductible is met, then moves into the 25% to 33% coinsurance phase. The good news: the Inflation Reduction Act of 2022 eliminated the old catastrophic-phase coinsurance and replaced it with a hard stop, the $2,100 annual out-of-pocket cap for 2026, so specialty tier coinsurance cannot run indefinitely across a calendar year.
Ten drugs negotiated under the Inflation Reduction Act now carry a Maximum Fair Price effective January 1, 2026, and two of them, Enbrel (etanercept, $2,355 per 30-day supply) and Stelara (ustekinumab, $4,695 per 30-day supply), are classic specialty tier biologics. Because Part D plans calculate coinsurance as a percentage of the negotiated price, a lower Maximum Fair Price directly reduces the dollar amount a beneficiary owes at 25% to 33% coinsurance, even though the percentage itself does not change. Patients on non-negotiated specialty drugs such as Humira, Ocrevus, Cosentyx, or Skyrizi do not get this direct benefit yet, but they still gain from the same $2,100 annual out-of-pocket cap and from growing biosimilar competition that has begun pulling list prices down across the specialty category.
What Specialty Tier Coinsurance Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same specialty tier coinsurance can cost many times more at a hospital than at your local pharmacy:
2026 Specialty Tier Coinsurance Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Retail cash price, specialty pharmacy (no insurance) | $2,000 - $15,000/month | Full list price at a specialty pharmacy (Accredo, CVS Specialty, Optum Specialty). Varies by drug: Humira and Enbrel run near the low end; Ocrevus and Skyrizi run near the high end. |
| Medicare Part B (provider-administered specialty biologic) | 20% coinsurance after $283 Part B deductible (2026) | Applies to infused specialty drugs given in a physician office or infusion suite (e.g., infliximab J1745, ustekinumab IV J3358). Billed under HCPCS J-codes at the Medicare ASP rate plus 6%. |
| Medicare Part D, specialty tier (Tier 5) | 25% - 33% coinsurance, capped at $2,100/year total (2026) | Applies once the $615 2026 Part D deductible is met. Median coinsurance is 25% for standalone PDPs and 28% for Medicare Advantage plans. All cost-sharing stops for the rest of the year once you hit $2,100. |
| Commercial insurance, specialty tier | 20% - 50% coinsurance or $100 - $250 flat fee per fill | Employer and ACA marketplace plans vary widely. Some cap specialty tier cost-sharing at a flat dollar amount per fill instead of an open percentage. Check your plan's Summary of Benefits. |
| Medicaid | $1 - $8/prescription (nominal copay, federal cap) | Federal Medicaid rules cap prescription copays at nominal amounts regardless of formulary tier. Most state Medicaid programs charge $1 to $4 for preferred specialty drugs and up to $8 for non-preferred. |
Coinsurance percentages and thresholds reflect CMS 2026 Part D benefit parameters and KFF's 2026 Medicare Part D cost-sharing analysis. Commercial plan cost-sharing varies by employer and state; check your Summary of Benefits and Coverage for exact specialty tier terms.
Source: CMS 2026 Part D Redesign Program Instructions, KFF Medicare Part D Enrollment Premiums and Cost Sharing in 2026
Why Hospitals Charge So Much
Hospital outpatient infusion suites and specialty pharmacies add facility and handling markups on top of the drug's acquisition cost, and specialty tier drugs see the largest dollar impact because their base price is already high. A biologic infusion that a specialty pharmacy dispenses for $6,500 can appear on a hospital outpatient bill at $12,000 to $40,000 once facility fees, nursing administration, and site-of-care markup are added. Site of care matters enormously for specialty tier drugs: the same infliximab infusion can cost 2 to 4 times more at a hospital outpatient department than at an independent infusion center or in a patient's home, because hospitals negotiate a separate, typically higher, facility fee on top of the drug charge.
Group purchasing organizations (GPOs) let hospitals acquire specialty drugs at negotiated wholesale rates, but those contracts do not cap what the facility bills the patient or insurer. Some hospitals also qualify for the federal 340B Drug Pricing Program, which lets them acquire specialty drugs at steep discounts, sometimes 25% to 50% below the average sales price, while still billing insurers at or near full price. This gap between acquisition cost and billed charge is one reason specialty tier drug bills from hospital-affiliated infusion centers run so much higher than the same drug administered at an independent site of care. Patients who receive a specialty drug bill that seems inflated can request an itemized statement and compare the drug charge line to the Medicare Part B Average Sales Price, published quarterly by CMS.
HCPCS J-Codes: What Appears on Your Bill
Provider-administered specialty biologics carry HCPCS Level II J-codes when billed under Medicare Part B in a physician office, infusion center, or hospital outpatient department. Self-administered specialty drugs (most auto-injector or oral biologics) have no J-code and instead run through Medicare Part D. Mixing up which channel a specialty drug bills through is one of the most common billing errors in this category.
HCPCS J-codes for Specialty Tier Coinsurance| Code | Description | What to look for |
|---|
| J0139 | Adalimumab (Humira, biosimilars) - per 1 mg, provider-administered only | Adalimumab is almost always self-injected at home and billed under Part D, not Part B. J0139 applies only in the rare case a clinician administers the dose in-office. If your Humira bill shows J0139 for a home injection, that is a coding error. |
| J3358 | Ustekinumab (Stelara, biosimilars), intravenous, per 1 mg | Applies to the IV induction dose given in a clinic or infusion suite; maintenance doses are typically self-injected and billed under Part D instead. Confirm which route your prescriber ordered before disputing a bill. |
| J1745 | Infliximab (Remicade, biosimilars), per 10 mg, provider-administered infusion | Infliximab is always infused in a clinical setting and billed under Part B at the ASP-plus-6% rate. Verify the units billed match your dose in milligrams; overbilling units is a frequent error for weight-based infusion dosing. |
J-code descriptions and rates reflect the 2026 Medicare Part B fee schedule. Self-administered specialty drugs (most auto-injector biologics) do not use J-codes and are billed under Part D instead.
Source: CMS Medicare Part B Average Sales Price files, CMS HCPCS Level II code set 2026
Patient Assistance Programs
Nearly every specialty tier biologic has a manufacturer patient assistance program (PAP) because the retail cost without insurance is prohibitive for most patients. Uninsured or underinsured patients at or below 400% of the federal poverty level can often receive the drug free through these programs. Patients who have commercial insurance but face a high specialty tier coinsurance should ask about the manufacturer's copay savings card first; that is a separate, faster-approval program from the income-based PAP, but it is blocked for anyone on Medicare, Medicaid, TRICARE, or VA benefits.
Patient assistance programs for Specialty Tier Coinsurance| Manufacturer program | Cost / Benefit | How to apply |
|---|
| myAbbVie Assist (Humira, Skyrizi, Rinvoq) | Free medication for uninsured or underinsured patients at or below 400% FPL | https://www.myabbvieassist.com/ |
| Amgen Safety Net Foundation (Enbrel) | Free Enbrel for income-eligible patients without adequate prescription coverage | https://www.amgensafetynetfoundation.com/ |
| Janssen CarePath (Stelara, Remicade) | Free or reduced-cost medication for eligible uninsured and underinsured patients | https://www.janssencarepath.com/ |
| Genentech Access Solutions (Ocrevus) | Free infused medication for income-qualified patients; separate copay assistance for commercially insured patients | https://www.genentech-access.com/ |
| Novartis Patient Assistance Foundation (Cosentyx) | Free medication for uninsured patients at or below 400% FPL | https://pap.novartis.com/ |
| NeedyMeds Drug Discount and State Pharmaceutical Assistance Directory | Free directory of manufacturer PAPs, state programs, and disease-specific foundations for specialty drugs | https://www.needymeds.org/ |
If you have Medicare, Medicaid, TRICARE, or VA benefits, manufacturer copay savings cards are blocked by the federal anti-kickback statute (42 U.S.C. 1320a-7b), which bars drug companies from subsidizing government-covered purchases. Use the income-based patient assistance program instead. Non-manufacturer resources like NeedyMeds and the Patient Advocate Foundation Co-Pay Relief Program remain available to Medicare and Medicaid beneficiaries.
Source: myAbbVie Assist, Amgen Safety Net Foundation, Janssen CarePath, Genentech Access Solutions, Novartis Patient Assistance Foundation, NeedyMeds.org
Medicare Part D
Medicare Part D plans place drugs into formulary tiers, and CMS requires that any drug priced above $950 per month in 2026 be classified as specialty tier, typically Tier 5. Federal rules require plans to charge coinsurance, a percentage of the negotiated price, rather than a flat copay for specialty tier drugs. The 2026 standard Part D deductible is $615; beneficiaries generally pay the full price of their specialty drug until that deductible is met, then move into the coinsurance phase at 25% to 33% depending on the plan.
The Inflation Reduction Act of 2022 (Public Law 117-169) restructured the Part D benefit so that the 2026 annual out-of-pocket cap of $2,100 applies across every tier, specialty included. Once a beneficiary's out-of-pocket spending on covered Part D drugs reaches $2,100 in a calendar year, cost-sharing drops to $0 for every remaining Part D prescription that year. Before this cap existed, catastrophic-phase coinsurance on specialty drugs had no ceiling, which is why specialty tier patients were the population most affected by the IRA's 2025 and 2026 Part D redesign. Manufacturer coupon programs, called savings or copay cards, can also apply toward reaching this cap for commercially insured patients, but federal law bars their use for Medicare beneficiaries.
Low-income Medicare beneficiaries can apply for the Part D Low-Income Subsidy (LIS), also called Extra Help, which reduces specialty tier cost-sharing to a fixed $0 to $5.10 for generics and $0 to $12.65 for brand or specialty drugs in 2026, replacing the 25% to 33% coinsurance entirely. Apply for LIS through the Social Security Administration at ssa.gov. Dual-eligible beneficiaries (those with both Medicare and Medicaid) are automatically enrolled in LIS. For beneficiaries who do not qualify for LIS but still cannot afford specialty tier coinsurance, the manufacturer's income-based patient assistance program is the next step, typically available at 300% to 400% of the federal poverty level.
Common Specialty Tier Coinsurance Billing Errors
Specialty tier billing has more failure points than a standard prescription because it often involves prior authorization, a separate specialty pharmacy, and sometimes both Part B and Part D channels for the same drug class. Check for these errors before paying a specialty drug bill:
- Copay accumulator blocking manufacturer coupon credit: some commercial plans do not count a manufacturer copay card's payment toward your deductible or out-of-pocket maximum. You may owe the full coinsurance again later in the year. As of 2026, 26 states have anti-accumulator laws for drugs without a medically appropriate generic.
- Prior authorization not on file: specialty tier drugs almost always require prior authorization. If the PA lapsed or was never filed, the pharmacy or infusion center may bill you the full cash price instead of your plan's coinsurance rate.
- Wrong billing channel (Part B vs Part D): an infused specialty drug billed incorrectly under Part D instead of Part B (or vice versa) can trigger a denial or an incorrect coinsurance calculation. Confirm with your prescriber's billing office which channel applies to your specific drug and site of administration.
- Coinsurance charged after the $2,100 annual cap is reached: once you hit the 2026 Part D out-of-pocket cap, you owe $0 for the rest of the year. If a specialty pharmacy still charges coinsurance after your plan confirms you crossed the cap, ask them to reprocess the claim.
- Biosimilar not substituted despite formulary preference: some plans moved a specialty tier brand to a lower tier once its biosimilar launched, but the pharmacy continued dispensing and billing the higher-tier brand. Ask your pharmacist to check whether a lower-cost biosimilar is now preferred on your formulary.
Frequently Asked Questions
What is specialty tier coinsurance and how is it different from a copay?
Specialty tier coinsurance is a percentage of a drug's negotiated price, typically 25% to 33% in 2026, charged instead of a flat dollar copay. CMS requires this coinsurance structure for any Part D drug priced above $950 per month, the 2026 specialty tier threshold. A flat copay might be $47 for a Tier 3 brand drug; coinsurance on a $7,000-per-month specialty biologic at 25% is $1,750 for that single fill, which is why specialty tier drugs generate the highest out-of-pocket bills in the Part D system until the annual out-of-pocket cap is reached.
What determines whether a drug is placed on the specialty tier in 2026?
CMS defines the specialty tier threshold at $950 per month for 2026: any Part D drug priced above that amount can be placed on the specialty tier, usually Tier 5. Plans must charge coinsurance rather than a flat copay for these drugs. Most biologics, oncology drugs, and other complex injectable or infused therapies fall above this threshold, though some high-cost oral specialty drugs (certain oncology pills) also qualify. Your plan's Evidence of Coverage document lists which specific drugs sit on its specialty tier.
Is there a generic or biosimilar for my specialty tier drug?
It depends on the drug. Specialty tier drugs are almost always biologics, so true small-molecule generics do not exist, but FDA-approved biosimilars do for several major specialty drugs: Amjevita and Cyltezo (biosimilars to Humira), Wezlana (biosimilar to Stelara), and Erelzi (biosimilar to Enbrel), each 30% to 85% cheaper than the reference brand. Ocrevus, Cosentyx, and Skyrizi have no FDA-approved biosimilar as of 2026. Ask your prescriber whether a biosimilar is clinically appropriate for your condition; switching can also move you to a lower, cheaper formulary tier.
How do I apply for a manufacturer patient assistance program for a specialty tier drug?
Search NeedyMeds.org or RxAssist.org by your drug's name to find the specific manufacturer program, such as myAbbVie Assist for Humira, Amgen Safety Net Foundation for Enbrel, or Janssen CarePath for Stelara. Most programs require proof of household income at or below 300% to 400% of the federal poverty level, a valid prescription, proof of US residency, and a statement that you lack adequate prescription drug coverage. Specialty biologic PAPs typically process applications in 5 to 15 business days and, if approved, ship the drug directly to your home or prescriber's office at no cost.
Can I use a manufacturer copay savings card with Medicare for a specialty tier drug?
No. Manufacturer copay savings cards cannot be used by anyone with Medicare, Medicaid, TRICARE, or VA benefits under the federal anti-kickback statute (42 U.S.C. 1320a-7b), which prohibits drug companies from subsidizing government-covered prescription purchases. If you have Medicare, apply for the manufacturer's separate income-based patient assistance program instead, or check whether you qualify for the Part D Low-Income Subsidy (Extra Help), which reduces specialty tier cost-sharing to $0 to $12.65 per fill in 2026.
What if my insurance denies coverage or requires step therapy for a specialty tier drug?
First, ask your prescriber to file a step-therapy override if the plan is requiring you to fail a cheaper alternative first; grounds include a prior documented trial and failure, a contraindication, or evidence of clinical harm from delay. If the drug itself is denied, file a formal appeal within 60 days with a letter of medical necessity, then request a peer-to-peer review between your prescriber and the plan's medical director. If internal appeals fail, escalate to the Independent Review Entity (Medicare Part D) or your state's external review process, and apply for the manufacturer's patient assistance program as a fallback.
Does the IRA Maximum Fair Price negotiation lower specialty tier coinsurance?
Indirectly, yes, for two specialty biologics. Enbrel (etanercept) and Stelara (ustekinumab) both carry an Inflation Reduction Act Maximum Fair Price effective January 1, 2026 ($2,355 and $4,695 per 30-day supply respectively). Since Part D coinsurance is calculated as a percentage of the negotiated price, a lower Maximum Fair Price directly lowers the dollar amount a beneficiary owes even though the 25% to 33% coinsurance rate itself does not change. Humira, Ocrevus, Cosentyx, and Skyrizi are not yet IRA-negotiated, so this benefit does not apply to them, though all specialty tier drugs benefit from the 2026 Part D $2,100 annual out-of-pocket cap.
What does a specialty tier drug cost without insurance in 2026, and how do I cap my out-of-pocket cost?
Cash prices for specialty tier biologics typically run $2,000 to $15,000 per month depending on the specific drug, filled through a specialty pharmacy rather than a retail counter. To cap your cost: enroll in Medicare Part D or a commercial plan to access the 2026 $2,100 annual out-of-pocket cap, apply for the manufacturer's patient assistance program if your income is at or below 400% of the federal poverty level, ask about a manufacturer copay card if you have commercial insurance, and apply for Medicare Extra Help (LIS) if you are low-income and Medicare-eligible.
